Sagimet Biosciences Inc.
SGMT
$2.21
$0.199.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.44% | -5.45% | 79.59% | 53.91% | 147.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.21% | 78.82% | 50.05% | 29.61% | 28.13% |
| Operating Income | -92.21% | -126.81% | -50.05% | -29.61% | -28.13% |
| Income Before Tax | -98.76% | -130.11% | -19.65% | -0.64% | -13.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -98.76% | -130.11% | -19.65% | -0.64% | -13.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.76% | -130.11% | -19.65% | -0.64% | -13.29% |
| EBIT | -92.21% | -126.81% | -50.05% | -29.61% | -28.13% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -44.76% | -30.24% | 99.29% | 99.36% | 99.11% |
| Normalized Basic EPS | -44.73% | -30.29% | 99.29% | 99.36% | 99.11% |
| EPS Diluted | -44.76% | -30.24% | 99.29% | 99.36% | 99.11% |
| Normalized Diluted EPS | -44.73% | -30.29% | 99.29% | 99.36% | 99.11% |
| Average Basic Shares Outstanding | 37.31% | 76.66% | 16,741.11% | 15,588.49% | 12,628.94% |
| Average Diluted Shares Outstanding | 37.31% | 76.66% | 16,741.11% | 15,588.49% | 12,628.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |